Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 64-Cu-Dotatate, 64Cu-DOTA-tyr3-Octreotate, Copper Cu 64 dotatate + [4] |
Target |
Action modulators |
Mechanism SSTR modulators(Somatostatin receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 Sep 2020), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC65H87CuN14O19S2 |
InChIKeyIJRLLVFQGCCPPI-QMVMUTFZSA-K |
CAS Registry1426155-87-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuroendocrine Tumors | United States | 03 Sep 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 3 | United States | 23 Aug 2018 |
Not Applicable | - | 64Cu-DOTATATE PET/CT | ymlrlycwko(bcqpimltsr) = ebsagcmwwu txqurmiott (ngxlmseijh ) View more | - | 01 Sep 2024 | ||
Not Applicable | - | Cu64-dotatate-PET/CT | ttbwhohavs(xivjacjfop) = jjzskutkix cfcbnhucuy (mxseuqmacr ) View more | - | 24 May 2024 | ||
Ga68-dotatate-PET/CT | ttbwhohavs(xivjacjfop) = skhdbatgge cfcbnhucuy (mxseuqmacr ) View more | ||||||
Phase 3 | 63 | lkxjwjzkpp = idtdubrlqp ngynfuzpeo (kgctgnifmy, uzuqrcfrxt - dmxnjrarjd) View more | - | 22 Dec 2022 | |||
Phase 3 | Somatostatinoma Somatostatin Receptor-Positive | 12 | barpsibgca(utyjpbquyz) = solipcxqxu gkjbspnxaq (crywrnprry ) View more | Positive | 01 Jun 2020 | ||
Not Applicable | - | pgklnwgpuz(vztrzufkgz) = jdfzxnnbwg nacuyurnwc (abysejwvby ) View more | - | 24 May 2016 | |||
pgklnwgpuz(vztrzufkgz) = bsksqekhwq nacuyurnwc (abysejwvby ) View more |